<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82014">
  <stage>Registered</stage>
  <submitdate>16/05/2007</submitdate>
  <approvaldate>16/05/2007</approvaldate>
  <actrnumber>ACTRN12607000263493</actrnumber>
  <trial_identification>
    <studytitle>Effects of exercise on reducing treatment-side effects in prostate cancer patients undergoing hormone therapy</studytitle>
    <scientifictitle>Resistance and aerobic exercise for reducing treatment side-effects in men receiving androgen deprivation therapy (ADT) for prostate cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None.</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate cancer, androgen deprivation therapy (ADT)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Exercise: progressive supervised aerobic (e.g. walking and cycling) and resistance exercises (e.g. upper and lower body resistance based exercise using weight machines) twice weekly (60 minutes session) during 12 weeks.</interventions>
    <comparator>Control: no treatment</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Muscle function: muscle strength and muscle endurance.</outcome>
      <timepoint>Baseline and post-test (12 weeks).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cardiorespiratory capacity: maximum oxygen uptake measured during a staged walking test on a motorized treadmill.</outcome>
      <timepoint>Baseline and post-test (12 weeks).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Physical performance: repeated chair rise, usual and fast 6-m walk, 6-m backwards walk, stair climb, and 400-m walk.</outcome>
      <timepoint>Baseline and post-test (12 weeks).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Body composition: whole body and regional muscle and fat tissue mass.</outcome>
      <timepoint>Baseline and post-test (12 weeks).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Balance and risk of falling: Neurocom Smart Balancemaster will be used to assess static and dynamic balance.</outcome>
      <timepoint>Baseline and post-test (12 weeks).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Health-related quality of life: EORTC QLQ-C30 and EORTC QLQ-PR25. 
</outcome>
      <timepoint>Baseline and post-test (12 weeks).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood markers: prostate specific antigen (PSA), testosterone, insulin, growth hormone, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and plasma glucose. </outcome>
      <timepoint>Baseline and post-test (12 weeks).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Prostate cancer patients undergoing androgen deprivation therapy for at least 2 months and who are anticipated to remain hypogonadal for the duration of the study (12 weeks), consent from physician, and able to walk 400m and undertake upper and lower body exercises.</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Bone metastases, musculoskeletal, neurological or cardiovascular disorder that could inhibit the participant from exercising, participated in regular (e.g. 2 to 3 times per week) resistance training in the previous 12 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by computer</concealment>
    <sequence>computerised sequence generation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Edith Cowan University</primarysponsorname>
    <primarysponsoraddress>100 Joondalup Drive, Joondalup, WA 6027</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The Cancer Council Western Australia</fundingname>
      <fundingaddress>46 Ventnor Avenue
West Perth 6005
Western Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Professor Robert Newton</sponsorname>
      <sponsoraddress>Vario Health Institute, 100 Joondalup Drive, Joondalup WA 6027</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The use of androgen deprivation therapy (ADT) to reduce testosterone levels in men with prostate carcinoma is accompanied by a number of adverse side effects. This study will investigate the effects of aerobic and resistance exercise on reversing musculoskeletal and cardiorespiratory related side effects in prostate cancer patients undertaking ADT.</summary>
    <trialwebsite />
    <publication>Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. A combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol.2010: 340347.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Edith Cowan University Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>23/04/2007</ethicapprovaldate>
      <hrec>07-53 GALVÃO</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Daniel Galvão</name>
      <address>School of Exercise, Biomedical and Health Sciences
Edith Cowan University
100 Joondalup Drive
Joondalup WA 6027</address>
      <phone>08-63045383</phone>
      <fax />
      <email>d.galvao@ecu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Daniel Galvão</name>
      <address>School of Exercise, Biomedical and Health Sciences
Edith Cowan University
100 Joondalup Drive, Joondalup, WA 6027</address>
      <phone>08-63045383</phone>
      <fax />
      <email>d.galvao@ecu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>